{"id":119626,"date":"2026-04-17T10:09:00","date_gmt":"2026-04-17T08:09:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=119626"},"modified":"2026-04-16T13:47:43","modified_gmt":"2026-04-16T11:47:43","slug":"rnatics-7-questions","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/119626\/rnatics-7-questions\/","title":{"rendered":"Rnatics: Hope for pulmonary fibrosis"},"content":{"rendered":"
\n

Munich Startup:<\/em><\/strong> <\/strong>What problem do you offer a solution for?<\/strong><\/strong><\/p>\n\n\n\n

Christina Beck, Clinical Development Project Manager: <\/em>We address acute and chronic pneumonia that can progress to pulmonary fibrosis in the long term. Our primary target indication is chronic and exacerbating idiopathic pulmonary fibrosis (IPF). Currently, there are only limited effective treatment options available for this disease, highlighting a significant unmet medical need.<\/p>\n\n\n\n

Munich Startup:<\/em><\/strong> What can you do as of today?<\/strong><\/strong><\/p>\n\n\n\n

Christina Beck:<\/em> With RCS-21<\/a> We are developing a novel, inhaled drug that targets specific cell types. It is an oligonucleotide that, using our Trimannose technology, selectively inhibits miR-21 in macrophages. This makes RCS-21 the first oligonucleotide specifically developed for the treatment of pneumonia and pulmonary fibrosis.<\/p>\n\n\n\n

More than 15 years of research before the company was founded<\/h2>\n\n\n\n

Munich Startup:<\/em><\/strong> What triggered the founding?<\/strong><\/strong><\/p>\n\n\n\n

Christina Beck:\u00a0 <\/em>The Founding<\/a> This followed over 15 years of research on miR-21 led by Stefan Engelhardt. Crucially, successful preclinical results with RCS-21, which we were also able to publish, were obtained. Furthermore, we received funding from the Federal Ministry of Education and Research (now: Federal Ministry of Research, Technology and Space) as part of the CoVmiR Grant program, as well as a positive recommendation from the Federal Institute for Drugs and Medical Devices (BfArM).<\/p>\n\n\n\n

Munich Startup:<\/em><\/strong> Was there ever a moment when you thought about giving up?<\/strong><\/strong><\/p>\n\n\n\n

Christina Beck:<\/em> No, not actually. Of course, there are always challenges, but we are convinced of our medication. Our goal is to give new hope to people with idiopathic pulmonary fibrosis and related diseases.<\/p>\n\n\n\n

Munich Startup:<\/em><\/strong> How would you know in a year that you're on the right track?<\/strong><\/strong><\/p>\n\n\n\n

Christina Beck:<\/em> We would primarily measure our progress by three milestones: positive results from the currently ongoing Phase I study, a successful Series A financing round, and the start of a Phase II study.<\/p>\n\n\n\n

Strong ecosystem & outstanding universities<\/h2>\n\n\n\n

Munich Startup:<\/em><\/strong> Would you start a business in Munich again, and why?<\/strong><\/strong><\/p>\n\n\n\n

Christina Beck:<\/em> Yes, absolutely. Munich offers a very strong startup ecosystem, for example with the IZB in Martinsried. In addition, the proximity to excellent research institutions like LMU and TUM facilitates close collaborations. Furthermore, we benefit from excellent networking and existing cluster initiatives such as the CNATM.<\/p>\n\n\n\n

Munich Startup:<\/em><\/strong> Perfection or speed?<\/strong><\/strong><\/p>\n\n\n\n

Christina Beck:<\/em> For us, it's a combination of both. High precision is essential in clinical development. At the same time, speed plays a crucial role in competition, and investors in particular pay attention to this.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Rnatics is developing RCS-21, a novel inhalable drug for pneumonia and idiopathic pulmonary fibrosis. The startup was founded in 2021 as a spin-off from the Technical University of Munich (TUM) by Stefan Engelhardt, together with Thomas Frischmuth and Klaus Rabe. Following promising research and an ongoing clinical trial, the team now aims to achieve the next milestones and create new treatment options for patients. Clinical Director and pharmacist Christina Beck explained the details of the company's founding and mission to us.<\/p>","protected":false},"author":42,"featured_media":119628,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5634,5638,4074,1083],"tags":[4202,371,4321,243,4498],"acf":[],"yoast_head":"\nRnatics: Hoffnung bei Lungenfibrose - Munich Startup<\/title>\n<meta name=\"description\" content=\"Rnatics entwickelt einen inhalativen Wirkstoff gegen Lungenfibrose. Das TUM-Spin-off treibt aktuell die klinische Entwicklung voran.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/119626\/rnatics-7-questions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rnatics: Hoffnung bei Lungenfibrose - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Rnatics entwickelt einen inhalativen Wirkstoff gegen Lungenfibrose. Das TUM-Spin-off treibt aktuell die klinische Entwicklung voran.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/119626\/rnatics-7-questions\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T08:09:00+00:00\" \/>\n<meta name=\"author\" content=\"Saskia Doll\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saskia Doll\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/\",\"url\":\"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/\",\"name\":\"Rnatics: Hoffnung bei Lungenfibrose - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2026\/04\/RNATICS_Gruppenfoto_Presse.jpg\",\"datePublished\":\"2026-04-17T08:09:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\"},\"description\":\"Rnatics entwickelt einen inhalativen Wirkstoff gegen Lungenfibrose. Das TUM-Spin-off treibt aktuell die klinische Entwicklung voran.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2026\/04\/RNATICS_Gruppenfoto_Presse.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2026\/04\/RNATICS_Gruppenfoto_Presse.jpg\",\"width\":1080,\"height\":736,\"caption\":\"Rnatics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rnatics: Hoffnung bei Lungenfibrose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\",\"name\":\"Saskia Doll\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"caption\":\"Saskia Doll\"},\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/doll\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2026\/04\/RNATICS_Gruppenfoto_Presse.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"736\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rnatics: Hope for pulmonary fibrosis - Munich Startup","description":"Rnatics is developing an inhalable drug to treat pulmonary fibrosis. The TUM spin-off is currently driving clinical development forward.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/119626\/rnatics-7-questions\/","og_locale":"en_US","og_type":"article","og_title":"Rnatics: Hoffnung bei Lungenfibrose - Munich Startup","og_description":"Rnatics entwickelt einen inhalativen Wirkstoff gegen Lungenfibrose. Das TUM-Spin-off treibt aktuell die klinische Entwicklung voran.","og_url":"https:\/\/cms.munich-startup.net\/en\/119626\/rnatics-7-questions\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2026-04-17T08:09:00+00:00","author":"Saskia Doll","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Saskia Doll","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/","url":"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/","name":"Rnatics: Hope for pulmonary fibrosis - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2026\/04\/RNATICS_Gruppenfoto_Presse.jpg","datePublished":"2026-04-17T08:09:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5"},"description":"Rnatics is developing an inhalable drug to treat pulmonary fibrosis. The TUM spin-off is currently driving clinical development forward.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2026\/04\/RNATICS_Gruppenfoto_Presse.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2026\/04\/RNATICS_Gruppenfoto_Presse.jpg","width":1080,"height":736,"caption":"Rnatics"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/119626\/rnatics-7-fragen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Rnatics: Hoffnung bei Lungenfibrose"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5","name":"Saskia Doll","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","caption":"Saskia Doll"},"url":"https:\/\/cms.munich-startup.net\/en\/author\/doll\/"}]},"og_image":[{"width":1080,"height":736,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2026\/04\/RNATICS_Gruppenfoto_Presse.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1776340064:25","_edit_last":"25","_yoast_wpseo_focuskw":"Rnatics","_yoast_wpseo_metadesc":"Rnatics entwickelt einen inhalativen Wirkstoff gegen Lungenfibrose. Das TUM-Spin-off treibt aktuell die klinische Entwicklung voran.","_yoast_wpseo_linkdex":"78","_thumbnail_id":"119628","wbounce_status":"default","_yoast_wpseo_primary_category":"5634","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"90","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"7 Fragen","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"1","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"3","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/119626"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/42"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=119626"}],"version-history":[{"count":2,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/119626\/revisions"}],"predecessor-version":[{"id":119629,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/119626\/revisions\/119629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/119628"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=119626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=119626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=119626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}